New drug duo aims to tackle aggressive bladder cancer
NCT ID NCT06879145
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This clinical trial is testing whether a combination of two drugs, SHR-A2102 and adebrelimab, works better than standard chemotherapy for people with muscle-invasive bladder cancer. The treatment is given before and after surgery to remove the bladder. The study involves 840 participants and aims to see if the new combination can improve outcomes like tumor response and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A2102 and adebrelimab (SHR-1316)
- What this could lead to
- If successful, this combination could offer a more effective perioperative treatment option for muscle-invasive bladder cancer, potentially improving survival and reducing recurrence.
- What could go wrong
- This is a phase II/III trial, so the treatment is still being tested for efficacy and safety. Side effects from the drug combination are possible, and it may not prove superior to standard chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCULAR INVASIVE BLADDER CANCER (MIBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact